Literature DB >> 17492896

Fampridine-SR for multiple sclerosis and spinal cord injury.

Keith C Hayes1.   

Abstract

Fampridine-SR is a sustained-release tablet form of the K(+) channel-blocking compound 4-aminopyridine that has been shown to restore conduction in focally demyelinated axons, to enhance synaptic transmission in many types of neurons and to potentiate muscle contraction. The present review describes the mechanism of action and chemistry of Fampridine-SR, its pharmacokinetics and safety, and the outcomes of clinical trials of its safety and efficacy for enhancing neuromuscular function in patients with multiple sclerosis or spinal cord injury. Randomized clinical trials completed to date indicate that this form of K(+) channel blockade may be useful for the improvement of walking ability in patients with multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492896     DOI: 10.1586/14737175.7.5.453

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  8 in total

Review 1.  4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Authors:  Henrik Boye Jensen; Mads Ravnborg; Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

2.  SMN is required for sensory-motor circuit function in Drosophila.

Authors:  Wendy L Imlach; Erin S Beck; Ben Jiwon Choi; Francesco Lotti; Livio Pellizzoni; Brian D McCabe
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

Review 3.  Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.

Authors:  Verena Isabell Leussink; Xavier Montalban; Hans-Peter Hartung
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

4.  Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.

Authors:  Keith C Hayes
Journal:  Neuropsychiatr Dis Treat       Date:  2011-04-28       Impact factor: 2.570

5.  A circuit-dependent ROS feedback loop mediates glutamate excitotoxicity to sculpt the Drosophila motor system.

Authors:  Jhan-Jie Peng; Shih-Han Lin; Yu-Tzu Liu; Hsin-Chieh Lin; Tsai-Ning Li; Chi-Kuang Yao
Journal:  Elife       Date:  2019-07-18       Impact factor: 8.140

6.  (4-Aminopyridine)-PLGA-PEG as a Novel Thermosensitive and Locally Injectable Treatment for Acute Peripheral Nerve Injury.

Authors:  Kristen M Manto; Prem Kumar Govindappa; Daniele Parisi; Zara Karuman; Brandon Martinazzi; John P Hegarty; M A Hassan Talukder; John C Elfar
Journal:  ACS Appl Bio Mater       Date:  2021-04-19

7.  Efficacy and safety of 9 nonoperative regimens for the treatment of spinal cord injury: A network meta-analysis.

Authors:  Da-Nian Ma; Xia-Qi Zhang; Jie Ying; Zhong-Jun Chen; Li-Xin Li
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

8.  Prolonged-Release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: A Pilot, Double-Blind, Randomized, Placebo-Controlled Study.

Authors:  François Jacques; Adrian Schembri; Avi Nativ; Chantal Paquette; Pawel Kalinowski
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.